, a provider of  early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab.  The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion’s global Phase I clinical network.  Celerion’s  approach employs new technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data. The system also identifies the small number of ECG recordings that will still require cardiologist review. This reduction in cardiologist involvement, combined with smaller overhead compared to traditional ECG Core labs supporting global clinical trials, allows Celerion to offer cost and time savings to clients.  
 
The Hybrid Phase I/ ECG Core lab was developed in collaboration with 

(Analyzing Medical Parameters for Solutions), and Global Instrumentation, LLC (GI).  AMPS-LLC is a world leader in high quality ECG analysis software utilized by many ECG Core labs.  Celerion is proud to host one of the first installations of AMPS’ FAT-QT and TrialPerfect software platforms, in addition to being one of the first contract research organization (CRO) to deploy the Global Instrumentation technology for Phase I/ ECG trials.  
 
“By integrating the ECG functions within our clinic network, minimizing traditional ECG overhead and providing more automation, Celerion enables fast access to data and cost-effective solutions that deliver high-quality data for the execution of thorough QT studies and ECG assessment in SAD and MAD programs,” said Susan Thornton, CEO of Celerion. 

According to Jim DeMaso, President of Global Instrumentation, “The GI M12R recorder and M12A Enterprise software provide Holter functions with full standard 12-lead ECG functionality in a centralized data management system designed for the requirements of clinical trials. We are pleased to be part of the Celerion/AMPS collaboration.”